Fructus cannabis extracted polypeptide with hypoglycemic function
Hemp seed-derived peptides address the limitations of current DPP-IV inhibitors by inhibiting DPP-IV and promoting GLP-1 and PYY secretion, providing effective blood glucose regulation with oral administration and reduced side effects.
Patent Information
- Application Number
- CN202311229430.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-21
- Publication Date
- 2025-03-21
AI Technical Summary
Current treatments for type 2 diabetes, such as DPP-IV inhibitors, often require injection due to long peptide sequences and potential side effects, limiting their application and convenience.
Development of a multi-peptide sequence derived from hemp seeds, specifically peptides like IPVIA, IPVA, IPTA, IPVVA, IPVPA, VVPL, VPKPL, VPSL, IPPA, VIPL, VPAL, VPVVL, VPIIL, HAYVFGVEDTLNALESGAIETLIVWENLDINR, and YVFGVEDTLNALESGAIETLIVWENLDINR, which can inhibit DPP-IV, promoting GLP-1 and PYY secretion, thereby regulating blood sugar levels without significant side effects and allowing oral administration.
The hemp-derived peptides effectively inhibit DPP-IV, enhancing glucose tolerance, improving insulin resistance, and balancing blood glucose levels with minimal side effects, offering a safer and more convenient treatment option compared to existing DPP-IV inhibitors.